Clinical Effect of Modified Gegen Qinlian Decoction Combined with Western Medicine on Children with Rotavirus Enteritis with Damp-Heat Syndrome

[Objectives] To explore the clinical effect of Modified Gegen Qinlian Decoction combined with western medicine on children with rotavirus enteritis with damp-heat syndrome and its influence on myocardial enzymes.

Effect of adjuvant oral immunoglobulin therapy on the illness of children with rotavirus enteritiss

Objective:To investigate the effect of adjuvant oral immunoglobulin therapy on the illness of children with rotavirus enteritis.Methods: A total of 170 children with rotavirus enteritis who were treated in the hospital between May 2016 and December 2017 were divided into control group (n=85) and immunoglobulin group (n=85) by random number table method. Control group received clinical routine therapy for rotavirus enteritis, immunoglobulin group received the oral immunoglobulin combined with routine therapy, and the treatment lasted for 7d. The differences in the contents of inflammatory factors, immunoglobulins and complements in serum as well as the levels of intestinal flora count in feces sample tissue were compared between the two groups before and after treatment.Results: Before treatment, the differences in the contents of inflammatory factors, immunoglobulins and complements in serum as well as the levels of intestinal flora count in feces samples were not statistically significant between the two groups of patients. After 7d of treatment, inflammatory factors IL-2, IL-6, IL-15 and TNF-α contents in serum of immunoglobulin group were lower than those of control group;IgG, IgA, IgM, C3 and C4 contents were higher than those of control group;bifidobacterium and lactobacillus count levels in feces samples were higher than those of control group whereas E. coli count level was lower than that of control group.Conclusion: Adjuvant oral immunoglobulin therapy can help to relieve the inflammatory response, enhance the immune function and balance the intestinal flora distribution in children with rotavirus enteritis.

Effects of Ribavirin combined with Clostridium butyricum powder on T lymphocyte subsets and inflammatory factors in child patients with rotavirus enteritis

Objective: To observe clinical efficacy of Ribavirin combined with Clostridium butyricum powder on child patients with rotavirus enteritis and analyze serum IL-6, IL-8, TNF-αconcentration and change of T lymphocyte subsets. Methods: A total of 90 patients with rotavirus enteritis were randomly divided into control group (n=45) and observation group (n=45). The control group was given conventional therapy combined with Ribavirin. The observation group was treated with Clostridium butyricum powder on the basis of control group. The changes of T lymphocyte subsets and inflammatory factors were measured before and after treatment in all subjects. Results: There was no significant difference in serum T lymphocyte subsets between the control group and the observation group before treatment. After treatment, the levels of serum CD3+, CD4+ and CD4+/CD8+ in both groups were higher than those before treatment, while CD8+ level was lower than that before treatment. The levels of serum CD3+, CD4+ and CD4+/CD8+ in the observation group were higher than those in the control group after treatment, while the CD8+ level was lower than that in control group in the corresponding period. There was no significant difference in the concentration of inflammatory factors between the control group and the observation group before treatment. After treatment, the levels of IL-6, IL-8 and TNF-α in the two groups were lower than those before treatment. The observation group was significantly lower than control group in corresponding period after treatment and difference was statistically significant. Conclusion: On the basis of conventional therapy and Ribavirin treatment, combined with Clostridium butyricum Powder for children with rotavirus enteritis can reduce concentration of inflammatory factors in peripheral blood and decrease expression of CD8+ T lymphocyte subsets level and improve the level of CD3+, CD4+ level. It is a potent effective drug for treatment of children with rotavirus enteritis.

Advances in Enteral Nutrition Strategies for Preterm Infants

With the continuous progress of medical care, the survival rate of preterm infants is increasing year by year, and adequate nutrition is crucial for the growth and development of preterm infants. Enteral nutrition (EN) is a nutritional support method that provides metabolically required nutrients and various other nutrients through the gastrointestinal tract, which is the best way to supply nutrition to preterm infants. A reasonable EN strategies can help improve the quality of survival, and long-term prognosis of preterm infants. This article summarizes and discusses the literature reports on EN for preterm infants at home and abroad in recent years, and reviews the research progress of EN strategies for preterm infants, personalized feeding programs, and related clinical problems affecting the establishment of EN, to provide reference for clinical work. EN for preterm infants requires the comprehensive use of a variety of research strategies and continuous exploration and innovation to provide better nutritional support for preterm infants and promote their healthy growth.

Multi-center Study of Enteral Feeding Practices in Hospitalized Late Preterm Infants in China

Objective To investigate the current enteral feeding practices in hospitalized late preterm infants in the Beijing area of China. Methods A multi-center, cross-sectional study was conducted. Infants born after 34 weeks and before 37 weeks of gestation were enrolled from 25 hospitals in the Beijing area of China from October 2015 to October 2017. Data on enteral feeding practices were collected and analyzed. Results A total of 1,463 late preterm infants were enrolled, with a mean gestational age（GA） of 35.6（34.9, 36.1） weeks. The percentage of exclusive breastfeeding was 4.5% at the initiation of enteral feeding but increased to 14.4% at discharge. When human milk was not available, most infants（46.1%） were fed with preterm infant formula. The rate of exclusive human milk feeding in infants born at 34 weeks gestation was higher than at discharge（21.1% of infants born at 34 weeks＇ GA versus 12.1% of infants born at 35 weeks＇ GA versus 12.3% of infants born at 36 weeks＇ GA, P 〈 0.001）. Only 28.4% of late preterm infants achieved full enteral feeding at discharge, and only 19.2% achieved 120 kcal/（kg·d） by enteral feeding at discharge. Importantly, 40.5% of infants did not regain the birth weight at discharge. Conclusion Enteral feeding support of late preterm infants has not been standardized to achieve optimal growth. Moreover, the human milk feeding rate was low, and many late preterm infants did not achieve the goal of enteral feeding and failed to regain birth weight at the time of discharge. More aggressive enteral feedings protocols are needed to promote human milk feeding and optimize growth for late preterm infants.

Effect of Aggressive Early High-Dose Intravenous Amino Acid Infusion and Early Trophic Enteral Nutrition on Very Low Birth Weight Infants

Objective: Very-low-birth-weight (VLBW) preterm infants are at risk of growth delay if they do not receive adequate nutritional support. This study evaluated the effect of aggressive early high-dose amino acid infusion plus early enteral trophic feeding on growth in VLBW infants within the first day of life. Study Design: The effect of a high-dose 3 g amino acid (HAA)/kg/d regimen beginning on the first day of life was compared with that of low-dose amino acid (LAA) supplementation at a dose of 0.5 or 1.0 g/kg/d. The primary outcome measures were the days of regained birth weight and achieved full enteral feeding. Result: Compared with the 19 infants in the LAA group, the 17 infants in the HAA group achieved significantly earlier full enteral feeding (7.8 ± 3.6 vs. 15.2 ± 8.9, p = 0.003) and regained birth weight (13.3 ± 3.8 vs. 17.5 ± 7.9, p = 0.047). In addition, shorter parenteral nutrition time was achieved by HAA administration (p Conclusion: Aggressive early simultaneous amino acid administration plus enteral feeding during the first few days of life for preterm infants was associated with improved weight gain and earlier full enteral feeding.

Efficacy,safety and immunogenicity of hexavalent rotavirus vaccine in Chinese infants

A randomized,double-blind,placebo-controlled multicenter trial was conducted in healthy Chinese infants to assess the efficacy and safety of a hexavalent live human-bovine reassortant rotavirus vaccine(HRV)against rotavirus gastroenteritis(RVGE).A total of 6400 participants aged 6-12 weeks were enrolled and randomly assigned to either HRV(n?3200)or placebo(n?3200)group.All the subjects received three oral doses of vaccine four weeks apart.The vaccine efficacy(VE)against RVGE caused by rotavirus serotypes contained in HRV was evaluated from 14 days after three doses of administration up until the end of the second rotavirus season.VE against severe RVGE,VE against RVGE hospitalization caused by serotypes contained in HRV,and VE against RVGE,severe RVGE,and RVGE hospitalization caused by natural infection of any serotype of rotavirus were also investigated.All adverse events(AEs)were collected for 30 days after each dose.Serious AEs(SAEs)and intussusception cases were collected during the entire study.Our data showed that VE against RVGE caused by serotypes contained in HRV was 69.21%(95%CI:53.31-79.69).VE against severe RVGE and RVGE hospitalization caused by serotypes contained in HRV were 91.36%(95%CI:78.45-96.53)and 89.21%(95%CI:64.51-96.72)respectively.VE against RVGE,severe RVGE,and RVGE hospitalization caused by natural infection of any serotype of rotavirus were 62.88%(95%CI:49.11-72.92),85.51%(95%CI:72.74-92.30)and 83.68%(95%CI:61.34-93.11).Incidences of AEs from the first dose to one month post the third dose in HRV and placebo groups were comparable.There was no significant difference in incidences of SAEs in HRV and placebo groups.This study shows that this hexavalent reassortant rotavirus vaccine is an effective,well-tolerated,and safe vaccine for Chinese infants.

Resolution of acute gastroenteritis symptoms in children and adults treated with a novel polyphenol-based prebiotic

AIM: To test efficacy and durability of a polyphenol-based prebiotic treatment for acute gastroenteritis in a 300 patient double-blinded clinical study.

儿童轮状病毒性肠炎季节性分布特征及预防策略探讨

目的 探究儿童轮状病毒性肠炎(RVE)季节性分布特征及预防策略。方法 选择2020年1月至2022年12月本院收治的腹泻患儿(246例)为研究对象,纳入训练集;根据RV抗原检测结果,分为RVE组(132例)和非RVE组(114例)。按照相同标准,另选腹泻患儿(82例)纳入验证集。收集患儿的临床资料,分析RVE发病季节及月份分布情况,以及两组患儿的临床资料和生化指标。采用多因素Logistic回归分析危险因素,构建列线图预测模型并评价。结果 本地区RVE多见于冬春季,其中12月至次年3月为RVE高发期,其发病情况占全年的59.09%。有吮指习惯、无餐前洗手习惯、非母乳喂养、有RVE患儿接触史、平均每天户外活动时间≤1h、无RV疫苗接种史、处于冬春季以及25(OH)D<35.5μg/L,均是RVE发生的独立危险因素(χ^(2)/t值分别为5.922、24.583、5.125、11.750、4.322、12.670、11.705、14.374,均P<0.05)。受试者工作特征(ROC)曲线评估列线图预测儿童RVE发病情况的曲线下面积(AUC)显示,训练集为0.924(95%CI:0.890~0.951)、验证集为0.912(95%CI:0.865~0.998);决策曲线分析法(DCA)曲线显示阈值概率在1%~91%时,净获益率>0。结论 本地区儿童RVE全年均可发病,多见于冬春季。有吮指习惯、无餐前洗手习惯、非母乳喂养、有RVE患儿接触史、平均每天户外活动时间≤1h、无RV疫苗接种史、处于冬春季以及25(OH)D<35.5μg/L均是RVE发生的独立危险因素。基于上述危险因素构建的列线图模型对儿童RVE发病情况具有较高的预测价值。临床应继续加强防控工作,重点保护易感者。

从“脾为之使”探讨五加减正气散治疗轮状病毒性肠炎的理论依据

轮状病毒性肠炎(Rotavirus enteritis,RVE)是婴幼儿严重腹泻的主要原因,给全球公共卫生带来严重负担。轮状病毒(Rotavirus,RV)可依赖宿主细胞侵袭多系统及靶器官,介导机体复杂的级联反应有效维持自身复制和增殖。该病属中医“温病”“泄泻”范畴,脾虚湿盛是基本病机,运脾化湿是主要治则。然中医之“脾”囊括了现代医学的多层含义,贯穿了“消化-神经-内分泌-免疫网络”始终。该文从脾统运化、枢气机、主卫外、内藏意等经典理论切入,系统梳理了“脾为五脏使”在RVE发病中的科学内涵,探讨了五加减正气散在RVE标本兼治中的理论依据,明确了“脾为之使”在中医药抗病毒中的指导作用,为临床从脾论治RVE丰富了思路与方法,为中医药抗病毒的传承发展提供了借鉴与参考。

重组人干扰素α-1b治疗小儿轮状病毒感染性肠炎的效果及安全性

目的:观察重组人干扰素α-1b治疗小儿轮状病毒感染性肠炎的效果及安全性。方法:选取2022年6月—2023年6月枝江市人民医院收治的186例小儿轮状病毒感染性肠炎,依据随机数表法分为对照组和观察组,各93例。对照组采用临床常规治疗及布拉氏酵母菌散,观察组在对照组基础上采用重组人干扰素α-1b,持续治疗3 d。比较两组治疗3 d后临床疗效,临床症状缓解情况,治疗前、治疗3 d后的肠黏膜损伤指标、肠道菌群、免疫功能,以及研究期间安全性。结果:治疗3 d后,观察组总有效率高于对照组;观察组腹痛消失时间、止泻时间、热退时间早于对照组;治疗3 d后,两组乳杆菌、双歧杆菌和大肠埃希菌菌落数较治疗前均升高,观察组高于对照组,两组粪肠球菌菌落数较治疗前均降低,观察组低于对照组;治疗3 d后,两组血清晚期糖基化终末产物(AGEs)、内毒素(ET)、二胺氧化酶(DAO)水平与治疗前相比均降低,观察组低于对照组;治疗3 d后,两组外周血CD4^(+)、CD4^(+)/CD8^(+)与治疗前相比均升高,观察组高于对照组,外周血CD8^(+)较治疗前均降低,观察组低于对照组;研究期间观察组不良反应发生率低于对照组;上述各指标比较,差异有统计学意义(P<0.05)。结论:在小儿轮状病毒感染性肠炎的临床治疗中,应用重组人干扰素α-1b,能明显改善患儿的临床症状,改善肠道菌群,增强机体免疫力,缓解肠道黏膜损伤,安全性较高,且疗效显著。

知信行健康宣教对轮状病毒肠炎患儿家属健康教育知识知晓度的影响研究

研究知信行健康宣教对轮状病毒肠炎患儿家属健康教育知识知晓度的影响。选取2021年6月—2023年10月广西壮族自治区南溪山医院收治的40例轮状病毒肠炎患儿为研究对象。采用随机数字表法将患儿分为两组,分别为对照组(n=20,实施常规宣教)和试验组(n=20,实施知信行健康宣教),比较两组患儿家属知识掌握程度和健康知识水平。结果显示,试验组患儿家属对知识的掌握情况优于对照组(P<0.05);护理前,两组患儿家属的健康知识水平比较,无统计学差异(P>0.05);护理后,试验组患儿家属的健康知识水平评分高于对照组(P<0.05)。研究发现,知信行健康宣教模式可增加轮状病毒肠炎患儿家属对疾病相关知识的了解,促使患儿更快康复。

早产儿肠内营养管理专家共识(2024年)

为早产儿尤其是极/超早产儿提供充足和均衡的营养是促进其正常生长发育和改善远期预后的物质基础,肠内营养是最佳的营养方式。既往系统回顾性分析显示使用基于循证医学的标准化喂养管理策略可有效促进全肠内喂养的建立,缩短肠外营养时间,改善早产儿的营养结局,而不增加坏死性小肠结肠炎或死亡的发生风险。基于国内外相关研究,该共识制订组采用证据推荐分级的评估、制订与评价方法(Grading of Recommendations Assessment,Development and Evaluation),从早产儿肠内营养的目标、过渡期的肠内营养、稳定生长期的肠内营养、肠内特殊营养素的补充及肠内营养的监测等5个方面提出20条推荐意见,旨在为相关从业人员提供早产儿肠内营养管理的建议,以改善早产儿的临床结局。

特殊情况的早产儿肠内营养管理专家共识(2024年)

早产儿出生后肠内营养的建立面临诸多挑战,尤其是存在一些特殊情况的早产儿,由于多种疾病因素和医疗干预妨碍肠内喂养的建立,造成这些早产儿的喂养目标、喂养的方式方法以及所面临的各种问题和解决方案充满了矛盾和争议。如何在保证安全的前提下,尽早建立肠内营养,尽快地达到全肠内喂养,是临床医师亟需解决的问题。该共识制订工作组基于国内外相关研究,采用证据推荐分级的评估、制订与评价方法(Grading of Recommendations Assessment,Development and Evaluation),形成了特殊情况的早产儿肠内营养管理专家共识,针对临床常见的9种特殊情况提出了14条推荐意见,旨在为相关从业人员提供特殊情况的早产儿肠内营养管理的建议,以改善这些早产儿的近远期预后。

不同剂量蒙脱石散治疗儿童轮状病毒肠炎的临床效果分析

目的:分析不同剂量蒙脱石散治疗儿童轮状病毒肠炎的临床效果。方法:选取2021年1月—2023年2月麻城市人民医院收治的轮状病毒肠炎患儿80例作为研究对象,随机分为两组,各40例。两组均给予常规治疗,对照组给予小剂量蒙脱石散治疗,观察组给予大剂量蒙脱石散治疗。比较两组临床症状转归时间、临床疗效。结果:观察组止泻时间、住院时间均短于对照组,差异有统计学意义(P<0.05)。观察组治疗总有效率高于对照组,差异有统计学意义(P=0.047)。结论:大剂量蒙脱石散治疗儿童轮状病毒肠炎的临床效果较好,能缩短临床症状转归时间。

初乳灌肠对极低出生体重儿胎粪排出和免疫反应的影响

目的探讨初乳灌肠对极低出生体重儿胎粪排出和免疫反应的影响。方法将128例极低出生体重儿随机分为干预组和对照组各64例。干预组采用2 mL/kg初乳灌肠;对照组采用1 mL/kg开塞露+1 mL/kg生理盐水1∶1稀释灌肠。灌肠自早产儿出生后24 h开始,至胎粪排尽时停止。结果干预组脱落10例,对照组脱落9例。干预组胎粪排尽时间和达到完全肠内营养时间显著短于对照组,体质量增长速度显著高于对照组(均P<0.05);干预组首次排出与排尽时的胎粪中的分泌型免疫球蛋A浓度、出生后第1次与第6天尿液中的分泌型免疫球蛋A浓度显著高于对照组(均P<0.05);干预组坏死性小肠结肠炎、喂养不耐受发生率显著低于对照组(均P<0.05)。结论初乳灌肠能促进极低出生体重儿胎粪排出,缩短达到完全肠内营养时间,提高体质量增长速度,提高早产儿免疫功能,降低相关并发症发生率。

早期肠道内营养对极低出生体重早产儿临床结局影响的Meta分析

目的系统评价早期肠道内营养对极低出生体重早产儿临床结局的影响。方法通过计算机检索有关极低出生体重早产儿应用早期肠道内营养后临床结局指标相关的文献,检索时间为建库起至2023年12月31日;数据提取后用RevMan5.4软件进行Meta分析。结果共筛选出323篇文献,最终纳入8篇,总样本量为3451例,Meta分析的结果显示,早期肠道内营养对极低出生体重早产儿住院时长[MD=-17.26,95%CI(-35.41,0.89),P=0.06]、NEC发病率[RR=0.98,95%CI(0.75,1.27),P=0.85]等无影响;但早期肠道内营养可以减少极低出生体重早产儿达全肠道内喂养时间[MD=-3.44,95%CI(-4.15,-2.73),P<0.00001]、静脉营养时间[MD=-5.90,95%CI(-10.42,-1.38),P=0.01]、喂养不耐受发生率[RR=0.70,95%CI(0.63,0.77),P<0.00001],感染发生率[RR=0.57,95%CI(0.42,0.76),P=0.0001]。结论早期肠道内营养能减少极低出生体重早产儿达全肠道营养时间、静脉营养时间、喂养不耐受发生率、感染发生率。

2018-2021年山西地区1283例住院病儿轮状病毒肠炎的流行病学特征及临床分析

目的了解山西地区儿童轮状病毒肠炎的流行病学及临床特征,分析重型轮状病毒肠炎危险因素,以早期识别重症病例,提高轮状病毒肠炎临床诊治水平及防控,从而减轻疾病负担。方法回顾性分析2018年1月至2021年12月于山西省儿童医院消化科住院治疗的急性腹泻病病儿3359例,总结轮状病毒肠炎流行病学特点及临床特征,并分析重型轮状病毒肠炎危险因素。结果2018年1月至2021年12月,因急性腹泻病入住消化科的住院病人3359例中轮状病毒检出1283例,检出率为38.20%;时间分布,每年12月至次年2月是轮状病毒感染高峰季节,8月、9月、10月最低;年龄分布,轮状病毒肠炎年龄(1.53±0.92)岁,>1~2岁年龄组检出率最高(52.16%),6个月至1岁年龄组次之;性别分布,男童检出率多于女童,比例为1.53∶1;地区分布,居住于城镇检出率显著高于农村;喂养方式分布,≤6个月病儿中,非母乳喂养检出率高于母乳喂养;轮状病毒肠炎住院天数(4.15±1.83)d,临床表现均为急性起病,主要表现为腹泻、呕吐、发热,常见合并症为脱水、代谢性酸中毒、电解质紊乱;轻型和重型轮状病毒肠炎在居住地区、年龄分组方面差异有统计学意义。经多因素分析,居住于乡村地区病儿发生重型轮状病毒肠炎的危险性是居住于城镇病儿的1.42倍。结论山西地区轮状病毒肠炎高发季节是冬季,多见于6个月至2岁的婴幼儿,男童比女童更易感染轮状病毒,居住于城镇相比农村更易感染。但居住于农村地区病儿更易发生重型轮状病毒肠炎。

Toll样受体4/核因子-κB p65通路对轮状病毒肠炎患儿肝损害的影响

目的探讨轮状病毒(RV)肠炎患儿Toll样受体4(TLR4)/核因子-κB(NF-κB)p56通路对肝损害的影响。方法选取50例RV肠炎患儿为RV组,另选取同期50例RV感染阴性的肠炎患儿为对照组。采用全自动生化分析仪检测患儿肝功能指标谷草转氨酶(AST)和谷丙转氨酶(ALT)水平。采用聚合酶链式反应(PCR)检测外周血单核细胞(PMBC)的TLR4 mRNA、NF-κB mRNA表达;采用蛋白质印迹法检测NF-κB p65蛋白表达水平。比较2组患儿血清AST、ALT水平和肝损害发生率。比较2组患儿PMBC的TLR4 mRNA、NF-κB mRNA和NF-κB p65蛋白表达。比较RV组中伴肝损害患儿和无肝损害患儿PMBC的TLR4 mRNA、NF-κB mRNA和NF-κB p65蛋白表达水平。采用Pearson相关分析法分析RV肠炎患儿肝功能与TLR4/NF-κB p65通路的相关性。结果RV组患儿血清AST、ALT水平及肝损伤发生率高于对照组,差异有统计学意义(P<0.05)。RV组患儿PBMC的TLR4 mRNA、NF-κB mRNA和NF-κB p65蛋白表达高于对照组,差异有统计学意义(P<0.05)。RV组中,伴肝损害患儿PBMC的TLR4 mRNA、NF-κB mRNA和NF-κB p65蛋白表达高于无肝损害患儿,差异有统计学意义(P<0.05)。RV肠炎患儿血清AST、ALT与TLR4 mRNA、NF-κB mRNA和NF-κB p65蛋白表达呈正相关(P<0.05)。结论RV肠炎患儿肝损害发生率较高,且与TLR4/NF-κB p65通路相关。TLR4/NF-κB p65通路过度激活可能是RV肠炎患儿发生肝损害的原因之一。

早期肠内营养治疗对早产儿营养状况及体格发育影响

目的:探讨早期肠内营养治疗对早产儿营养状况、体格发育的影响,以及并发症发生情况。方法:选取2020年1月—2023年10月在芜湖市第二人民医院分娩出生,并接受住院分娩和治疗的100例早产儿为研究对象,将100例早产儿按照随机数字表分为观察组(出生后24 h内即给予肠内营养治疗)和对照组(出生24 h后给予肠内营养治疗)。早期肠内营养治疗组,在出生后24 h内给予肠内营养治疗,对照组早产儿在出生24 h后给予肠内营养,肠内营养喂养量、方式、增加速度均与观察组一致。比较两组早产儿入院时和7 d龄血清营养指标,包括白蛋白(ALB)、前白蛋白(PA)、血红蛋白(HGB)及转铁蛋白(TRF);比较入院时、7 d龄和14 d龄体格发育指标,包括身长、体质指数(BMI)和头围;以及喂养不耐受、胆汁淤积、坏死性小肠结肠炎、败血症等并发症发生情况。结果:早期肠内营养组早产儿在7 d龄时血清ALB、PA、HGB、TRF水平显著高于对照组早产儿(P<0.05)。体格发育指标上,两组早产儿入院时及7 d龄BMI、身长及头围无差异(P>0.05),在14 d龄时,两组早产儿身长及头围仍无差异,而早期肠内营养治疗组早产儿BMI高于对照组(P=0.012)。早期肠内营养治疗组早产儿并发症发生率为18%,对照组为36%,差异有统计学意义(P=0.043)。结论:给予早产儿早期肠内营养治疗可改善其营养状况,促进生长发育,且并发症总发生率并未增加,故在早产儿常规治疗的基础上,应及早对其进行肠内营养治疗。